Lay summary
Chronic kidney disease (CKD) affects 11% of the Aotearoa New Zealand population. It is more common in indigenous people impacting one-quarter of Māori and one-third of Pacific Peoples in Aotearoa New Zealand. In many people CKD progresses to kidney failure, a devastating event for the person and their whānau causing poor wellbeing, poor survival, and the need for dialysis or kidney transplantation. Although there are treatments for CKD that can delay kidney failure, for many people these treatments fail. Combining treatments, which have different mechanisms of action, has the potential to be helpful. CAPTIVATE (The Chronic kidney disease Adaptive Platform Trial Investigating Various Agents for Therapeutic Effect) is a landmark multi-national trial that will identify the best treatments and treatment combinations that will slow the progression of CKD to kidney failure. Recruiting in Australia, India, Spain, Sri Lanka and Aotearoa New Zealand, we will recruit 100 Kiwis.